Lyell Immunopharma, Inc.LYELNASDAQ
LOADING
|||
Cash Flow Under Pressure
Profitability under pressure
Left:
||||
Operating cash flow minus capital expenditures
Latest
$-162.86M
Near historical average
Average (5y)
$-150.63M
Historical baseline
Range
High:$23.43M
Low:$-212.35M
CAGR
NaN%
Modest growth trend
| Period | Value | Change |
|---|---|---|
| 2024 | $-162.86M | +2.1% |
| 2023 | $-166.38M | +14.2% |
| 2022 | $-193.83M | -1.1% |
| 2021 | $-191.75M | +9.7% |
| 2020 | $-212.35M | -1006.5% |
| 2019 | $23.43M | - |